Sökning: onr:"swepub:oai:gup.ub.gu.se/196927" >
Once-daily fluticas...
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.
-
O'Byrne, Paul M (författare)
-
Bleecker, Eugene R (författare)
-
Bateman, Eric D (författare)
-
visa fler...
-
Busse, William W (författare)
-
Woodcock, Ashley (författare)
-
Forth, Richard (författare)
-
Toler, William T (författare)
-
Jacques, Loretta (författare)
-
- Lötvall, Jan, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Krefting Research Centre
-
visa färre...
-
(creator_code:org_t)
- 2013-10-17
- 2014
- Engelska.
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 43:3, s. 773-82
- Relaterad länk:
-
https://erj.ersjourn...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The inhaled corticosteroid fluticasone furoate (FF) and the long-acting β₂ agonist vilanterol (VI) are in development as a combined once-daily therapy for asthma and chronic obstructive pulmonary disease. Our study objectives were to compare the efficacy and safety of once-daily FF/VI with FF alone and twice-daily fluticasone propionate (FP) in patients aged ≥12 years with moderate-to-severe persistent asthma. Patients (n=586) received FF/VI 200/25 μg or FF 200 μg once-daily (evening dosing), or FP 500 μg twice-daily for 24 weeks. Co-primary end-points were change from baseline in trough forced expiratory volume in 1 s (FEV₁) weighted mean (wm) 0-24 h serial FEV1. Secondary end-points included change from baseline in percentage of rescue-free 24-h periods, percentage of symptom-free 24-h periods and total Asthma Quality of Life Questionnaire (AQLQ). Safety assessments included adverse events, 24-h urinary cortisol excretion, vital signs and ECG. FF/VI significantly improved trough FEV1 and wmFEV₁ versus FF and FP. Significantly more rescue-free and symptom-free 24-h periods were reported with FF/VI versus FF. Treatment differences for AQLQ were not significant. Incidence of adverse events was similar across groups. No clinically significant differences were seen for 24-h urinary cortisol excretion, vital signs or ECG. FF/VI resulted in statistically greater improvements in lung function and symptomatic end-points versus FF, and was well tolerated in this asthma population.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
O'Byrne, Paul M
-
Bleecker, Eugene ...
-
Bateman, Eric D
-
Busse, William W
-
Woodcock, Ashley
-
Forth, Richard
-
visa fler...
-
Toler, William T
-
Jacques, Loretta
-
Lötvall, Jan, 19 ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Lungmedicin och ...
- Artiklar i publikationen
-
The European res ...
- Av lärosätet
-
Göteborgs universitet